ICICI Direct's research report on Dr Reddys Laboratories
Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations. Revenue breakup: US (37%), India (18%), Russia and CIS (12%), Europe (8%), RoW (6%) and API (17%) It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe
Outlook
We value Dr Reddy’s at Rs 5160 i.e. 21x FY24E EPS of Rs 238.4 + NPV of Rs 154.1 for gRevlimid.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
